Search clinical trials for: Glycogenosis type II

Total 83469 results

Genzyme, a Sanofi Company

Recruiting

Pompe Pregnancy Sub-Registry

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Glycogenesis 2 Acid Maltase Deficiency

Croatia, United States, Italy, Belgium, Czechia
Genzyme, a Sanofi Company

Recruiting

Pompe Disease Registry Protocol

Glycogen Storage Disease Type II | Pompe Disease

Hungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
Genzyme, a Sanofi Company

Completed

Pompe Lactation Sub-Registry

Glycogen Storage Disease | Pompe Disease

United States
Fundació Institut de Recerca de l'Hospital de la...
Genzyme, a Sanofi Company

Unknown

Search for Serum/Plasma Biomarkers in Pompe's Disease (BIOPOMPE)

Pompe Disease | Late Onset Pompe Disease

Spain
Genzyme, a Sanofi Company

Terminated

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

Glycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)

United States, Taiwan, Germany
Genzyme, a Sanofi Company

Completed

Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

Pompe Disease

United States
Genzyme, a Sanofi Company

Completed

A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

Glycogen Storage Disease Type II

United States, France, Netherlands
Genzyme, a Sanofi Company

Completed

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

United States, France, Netherlands
Genzyme, a Sanofi Company

Completed

Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease

Glycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease

United States
Genzyme, a Sanofi Company

Completed

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

Glycogen Storage Disease Type II

United States, France, Germany, Israel, Italy, Netherlands, Taiwan
Genzyme, a Sanofi Company

Completed

A Study of rhGAA in Patients With Late-Onset Pompe Disease

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

Netherlands
Genzyme, a Sanofi Company

Approved for marketing

Alglucosidase Alfa Temporary Access Program (ATAP)

Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)

United States
Genzyme, a Sanofi Company

Completed

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

Glycogen Storage Disease Type II | Glycogenosis 2

United States
Genzyme, a Sanofi Company

Completed

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

Glycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease

United States
Genzyme, a Sanofi Company

Completed

Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

France
Genzyme, a Sanofi Company

Approved for marketing

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease

Glycogen Storage Disease Type II | Glycogenosis 2
Genzyme, a Sanofi Company

Completed

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

Glycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease

United States, Israel, France, United Kingdom
Genzyme, a Sanofi Company

Completed

A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease

Glycogen Storage Disease Type II

United States, Taiwan, Israel, United Kingdom, France
Fundació Institut de Recerca de l'Hospital de la...
Genzyme, a Sanofi Company

Unknown

A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI (POMPE 2013)

Pompe Disease

Spain
Clinica Universidad de Navarra, Universidad de...
Biobizkaia; Genbioma Aplicaciones S.L.

Not yet recruiting

Effect of a Postbiotic Intake on Glucose Control and Microbiota Composition of Type 2 Diabetic Subjects: a Randomized Controlled Trial. (Diabet2Predict)

Diabetes Mellitus, Type 2

Spain
University Hospital, Montpellier

Not yet recruiting

Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma (MERCCALIBI)

Merkel Cell Carcinoma
Institute of Hematology & Blood Diseases Hospital...

Recruiting

VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT (VMAC+DLI)

Relapse Acute Myeloid Leukemia

China
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited

Not yet recruiting

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Recurrent Clear Cell Renal Cell Carcinoma | Stage II Renal Cell Cancer American Joint Committee on Cancer...

United States
Washington University School of Medicine

Not yet recruiting

Propranolol for the Treatment of Kaposi Sarcoma in Adults

Kaposi Sarcoma

United States
Lei Liu

Not yet recruiting

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
University of Washington

Not yet recruiting

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal Zone Lymphoma and other conditions

United States
Ruijin Hospital

Not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Diffuse Large B-Cell Lymphoma
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
Virginia Commonwealth University

Not yet recruiting

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial (CBT-I in PBT)

Glioblastoma | Astrocytoma | Oligodendroglioma | Meningioma | Primary Brain Tumor | Primary Central Nervous System (CNS) Lymphoma

United States
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma

Spain
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Advanced Cholangiocarcinoma | FGFR2 Fusion

United States
Atlantic Health System
Regeneron Pharmaceuticals

Not yet recruiting

Atlantic Lipid Lowering Treatment Optimization Program (ALLTOP)

Familial Hypercholesterolemia | High Density Lipoprotein Deficiency | Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia | Apolipoprotein B 100, Familial Defective | Low-Density-Lipoid-Type Hyperlipoproteinemia

United States
Massachusetts General Hospital
National Cancer Institute (NCI); Fred Hutchinson Cancer Center; University of... and other collaborators

Not yet recruiting

Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (HOPE II)

Hiv | Human Papilloma Virus
Roswell Park Cancer Institute

Not yet recruiting

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Unresectable Triple-Negative Breast Carcinoma

United States
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Cold Atmospheric Plasma for the Endoscopic Treatment of Duodenal Polyps in Patients With Familial Adenomatous Polyposis (coldAPC)

Familial Adenomatous Polyposis | Adenomatous Polyposis Coli | Duodenal Adenoma

Germany
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

T-lymphoblastic Lymphoma | T-lymphoblastic Leukemia

China
Jonsson Comprehensive Cancer Center
Boston Scientific Corporation

Not yet recruiting

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
Chong Kun Dang Pharmaceutical

Recruiting

Efficacy and Safety of Telmisartan Compared With Losartan

Hypertension | Diabetic Nephropathies

Korea, Republic of
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study

Pheochromocytoma

China
University of Colorado, Denver

Not yet recruiting

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Leukemia | Myeloid Leukemia | Monocytic Leukemia

United States
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Acute Lymphoid Leukemia

China
Henan Cancer Hospital

Not yet recruiting

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell
Peking University People's Hospital
Akeso Pharmaceuticals, Inc.

Not yet recruiting

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Peking University Cancer Hospital & Institute

Not yet recruiting

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

Melanoma | Metastatic Melanoma | Mucosal Melanoma

China
Celgene

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)

Lymphoma, Follicular

United States, Australia, Brazil, Canada, Chile, France, Germany, Italy, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Undifferentiated Pleomorphic Sarcoma | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Radboud University Medical Center

Not yet recruiting

The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II (RAID-II)

Inflammation | Diabetes Mellitus, Type 1
Mayo Clinic

Recruiting

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Yanyan Liu

Recruiting

Linperlisib Combined With Chidamide in Patients With PTCL

Peripheral T-cell Lymphoma

China

Search clinical trials for: Glycogenosis type II

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations